Molecular mechanism of hepatocarcinogenesis

Journal of Gastroenterology and Hepatology (Australia)

Volumn 12, Issue 9-10, 1997, Pages

  Sheu, Jin Chuan ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Clonality; HBV; HCV; Hepatocellular carcinoma; Microsatellite; P53; Telomerase

Indexed keywords

PROTEIN P53; TELOMERASE;

CANCER SURVIVAL; CHROMOSOME 11; CHROMOSOME 13; CHROMOSOME 16; CHROMOSOME 17; CONFERENCE PAPER; DNA FINGERPRINTING; ENZYME ACTIVITY; GENE DELETION; HETEROZYGOSITY LOSS; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CARCINOGENESIS; MOLECULAR DYNAMICS; POINT MUTATION; PRIORITY JOURNAL; RNA ANALYSIS; VIRUS DETECTION;

EID: 0030733924     PISSN: 08159319     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1746.1997.tb00514.x     Document Type: Conference Paper

References (58)

1. Linsell DA, Higginson J. The geographic pathology of liver cell cancer. In: Cameron HM, Linsell DA, Warwick GP, eds. Liver cell cancer. New York: Elsevier, 1976; 1-16.
2. Beasley RP. Hepatitis B virus as the etiologic agent in hepatocellular carcinoma: Epidemiologic considerations. Hepatology 1982; 2: S21-6.
3. Chen DS, Kuo GC, Sung JL et al. Hepatitis C virus infection in an area hyperendemic for hepatitis B and chronic liver disease: The Taiwan experience. J. Infect. Dis. 1990; 162: 817-22.
4. Sheu JC, Wang JT, Wang TH et al. Prevalence of hepatitis C viral infection in a community in Taiwan: Detection by synthetic peptide-based assay and polymerase chain reaction. J. Hepatol. 1993; 17: 192-8.
5. Sheu JC, Huang GT, Shih LN et al. Hepatitis C and B viruses in hepatitis B surface antigen negative hepatocellular carcinoma. Gastroenterology 1992; 103: 1322-7.
6. Nigro JM, Baker SJ, Preisinger AC et al. Mutations in the p53 gene occur in diverse human tumour types. Nature 1989; 342: 705-8.
7. Levine AJ, Momand J, Finlay CA. The p53 tumour suppressor gene. Nature 1991; 351: 453-6.
8. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991; 253: 49-53.
9. Bressac B, Galvin KM, Liang TJ, Isselbacher KJ, Wands JR, Ozturk M. Abnormal structure and expression of p53 gene in human hepatocellular carcinoma. Proc. Natl Acad. Sci. USA 1990; 87: 1973-7.
10. Hsu IC, Metcalf RA, Sun T, Welsh JA, Wang NJ, Harris CC. Mutational hotspot in the p53 gene in human hepatocellular carcinomas. Nature 1991; 350: 427-8.
11. Bressac B, Kew M, Wands J, Ozturk M. Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. Nature 1991; 350: 429-31.
12. Sheu JC, Huang GT, Lee PH et al. Mutation of p53 gene in hepatocellular carcinoma in Taiwan. Cancer Res. 1992; 52: 6098-100.
13. Fountain JW, Karayiorgou M, Ernstoff MS et al. Homozygous deletions within human chromosome band 9p21 in melanoma. Proc. Natl Acad. Sci. USA 1992; 89: 10 557-61.
14. Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 1993; 366: 704-7.
15. Nobori T, Miura K, Wu DJ, Lois A, Takabayashi K, Carson DA. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 1994; 368: 753-6.
16. Kamb A, Gruis NA, Weaver Feldhaus-J et al. A cell cycle regulator potentially involved in genesis of many tumour types. Science 1994; 264: 436-40.
17. Caldas C, Hahn SA, da Costa LT et al. Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nature Genet. 1994; 8: 27-32.
18. Spruck CH III, Gonzalez Zulueta M, Shibata A et al. p16 gene in uncultured tumours. Nature 1994; 370: 183-4 (Letter).
19. Cairns P, Mao L, Merlo A et al. Rates of p16 (MTS1) mutations in primary tumours with 9p loss. Science 1994; 265: 415-17 (Letter).
20. Okamoto A, Demetrick DJ, Spillare EA et al. Mutations and altered expression of p16INK4 in human cancer. Proc. Natl Acad. Sci. USA 1994; 91: 11 045-9.
21. Sheu JC, Sung JL, Chen DS et al. Early detection of hepatocellular carcinoma by real-time ultrasonography. A prospective study. Cancer 1985; 56: 660-6.
22. Sheu JC, Chen DS, Sung JL et al. Hepatocellular carcinoma: US evolution in the early stage. Radiology 1985; 155: 463-7.
23. Sheu JC, Huang GT, Chen DS et al. Small hepatocellular carcinoma: Intratumour ethanol treatment using new needle and guidance systems. Radiology 1987; 163: 43-8.
24. Lee CS, Sung JL, Hwang LY et al. Surgical treatment of 109 patients with symptomatic and asymptomatic hepatocellular carcinoma. Surgery 1986; 99: 481-90.
25. Hsu HC, Wu TT, Wu MZ, Sheu JC, Lee CS, Chen DS. Tumour invasiveness and prognosis in resected hepatocellular carcinoma. Clinical and pathogenetic implications. Cancer 1988; 61: 2095-9.
26. Lee CS, Sheu JC, Wang M, Hsu HC. Long-term outcome after surgery for asymptomatic small hepatocellular carcinoma. Br. J. Surg. 1996; 83: 330-3.
27. Lee PH, Lin WJ, Tsang YM et al. Clinical management of recurrent hepatocellular carcinoma. Ann. Surg. 1995; 222: 670-6.
28. Esumi M, Aritaka T, Arii M et al Clonal origin of human hepatoma determined by integration of hepatitis B virus DNA. Cancer Res. 1986; 46: 5767-71.
29. Govindarajan S, Craig JR, Valinluck B. Clonal origin of hepatitis B virus-associated hepatocellular carcinoma. Hum. Pathol. 1988; 19: 403-5.
30. Chen PJ, Chen DS, Lai MY et al. Clonal origin of recurrent hepatocellular carcinomas. Gastroenterology 1989; 96: 527-9.
31. Shimoda A, Kaneko S, Uchijima M et al. Clonal origin of mammalian hepatitis B virus-related hepatocellular carcinoma. J. Med. Virol. 1990; 30: 282-6.
32. Hsu HC, Chiou TJ, Chen JY, Lee CS, Lee PH, Peng SY. Clonality and clonal evolution of hepatocellular carcinoma with multiple nodules. Hepatology 1991; 13: 923-8.
33. Liang XH. Clonal origin of intrahepatic recurrence after resection of hepatocellular carcinoma. Chung Hua Chung Lui Tsa Chih 1991; 13: 2-4. (in Chinese with English abstract).
34. Sheu JC, Huang GT, Chou HC, Lee PH, Wang JT, Chen DS. Multiple hepatocellular carcinomas at the early stage have different clonality. Gastroenterology 1993; 105: 1471-6.
35. Buetow KH, Murray JC, Israel JL et al. Loss of heterozygosity suggests tumour suppressor gene responsible for primary hepatocellular carcinoma. Proc. Natl Acad. Sci. USA 1989; 86: 8852-6.
36. Zhang WD, Hirohashi S, Tsuda H et al. Frequent loss of heterozygosity on chromosomes 16 and 4 in human hepatocellular carcinoma. Jpn. J. Cancer Res. 1990; 81: 108-11.
37. Fujimori M, Tokino T, Hino O et al. Allelotype study of primary hepatocellular carcinoma. Cancer Res. 1991; 51: 89-93.
38. Walker GJ, Hayward NK, Falvey S, Cooksley WG. Loss of somatic heterozygosity in hepatocellular carcinoma. Cancer Res. 1991; 51: 4367-70.
39. Emi M, Fujiwara Y, Nakajima T et al. Frequent loss of heterozygosity for loci on chromosome 8p in hepatocellular carcinoma, colorectal cancer, and lung cancer. Cancer Res. 1992; 52: 5368-72.
40. Takahashi K, Kudo J, Ishibashi H, Hirata Y, Niho Y. Frequent loss of heterozygosity on chromosome 22 in hepatocellular carcinoma. Hepatology 1993; 17: 794-9.
41. Cawkwell L, Bell SM, Lewis FA, Dixon MF, Taylor GR, Quirke P. Rapid detection of allele loss in colorectal tumours using microsatellites and fluorescent DNA technology. Br. J. Cancer 1993; 67: 1262-7.
42. Thibodeau SN, Bren G, Schaid D. Microsatellite instability in cancer of the proximal colon. Science 1993; 260: 816-19.
43. Peltomaki P, Aaltonen LA, Sistonen P et al. Genetic mapping of a locus predisposing to human colorectal cancer. Science 1993; 260: 810-12.
44. Cunningham C, Dunlop MG, Wyllie AH, Bird CC. Deletion mapping in colorectal cancer of a putative tumour suppressor gene in 8p22-p21.3. Oncogene 1993; 8: 1391-6.
45. Weissenbach J, Gyapay G, Dib C et al. A second-generation linkage map of the human genome. Nature 1992; 359: 794-801.
46. Harley CB, Villeponteau B. Telomeres and telomerase in aging and cancer. Curr. Opin. Genet. Dev. 1995; 5: 249-55.
47. Harley CB. Telomere loss: Mitotic clock or genetic time bomb? Mutat. Res. 1991; 256: 271-82.
48. Harley CB, Futcher AB, Greider CW. Telomeres shortening during aging of human fibroblasts. Nature 1990; 345: 458-60.
49. Hastie ND, Dempster M, Dunlop MG, Thompsson AM, Green DK, Allshire RC. Telomere reduction in human colorectal carcinoma and with aging. Nature 1990; 346: 866-8.
50. Allsopp RC, Vaziri H, Patterson C et al. Telomere length predicts replicative capacity of human fibroblasts. Proc. Natl Acad. Sci. USA 1992; 89: 10 114-18.
51. Shay JW, Werbin H, Wright EW. Telomere shortening may contribute to aging and cancer: A perspective. Mol. Cell. Diff. 1994; 2: 1-21.
52. Hiyama E, Yokoyama T, Hiyama K et al. Alteration of telomeric repeat length in adult and childhood solid neoplasias. Int. J. Oncol. 1995; 6: 13-16.
53. Kim NW, Piatyszek MA, Prowse KR et al. Specific association of human telomerase activity with immortal cells and cancer. Science 1994; 266: 2011-15.
54. Counter CM, Hirte HW, Bacchetti S, Harely CB. Telomerase activity in human ovarian carcinoma. Proc. Natl Acad. Sci. USA 1994; 91: 2900-4.
55. Hiyama E, Gollahon L, Kataoka T et al. Telomerase activity in human breast tumours. J. Natl Cancer Inst. 1996; 88: 116-22.
56. Tahara H, Kuniyasu H, Yokozaki H et al. Telomerase activity in preneoplastic and neoplastic gastric and colorectal lesions. Clin. Cancer Res. 1995; 1: 1245-51.
57. Tahara H, Nakanishi T, Kitamoto M et al. Telomerase activity in human liver tissues: Comparison between chronic liver disease and hepatocellular carcinoma. Cancer Res. 1995; 55: 2734-6.
58. Piatyszek MA, Kim NW, Weinrich SL et al. Detection of telomerase activity in human cells and tumours by a telomeric repeat amplification protocol (TRAP). Methods Cell. Sci. 1995; 17: 1-15.